We are delighted to announce a collaboration with the Cell and Gene Therapy Catapult (CGTC), an Innovate UK funded organisation, to accelerate the development of AAV based gene therapy treatments.
Since 2015, dementia has been one of the leading causes of mortality in the UK. Whilst new and improved treatments for heart disease and cancer are reducing mortality, a lack of effective treatment options for neurodegenerative conditions means that dementia-related deaths continue to rise.
Through this collaboration, the UK DRI and other academic centres of excellence will work with the CGT Catapult, to identify new AAV-based gene therapies with high potential to become new medicines for dementia, assessing a wide range of assets in order to best address the significant unmet medical need. The collaborators will then create detailed development plans for each project and potentially conduct early research activities in order to prepare assets for further investment.